Enibarcimab
Based on 1 publication(s) in Google Scholar
Enibarcimab is a humanized, non-neutralizing monoclonal antibody targeting adrenomedullin (ADM). Enibarcimab binds to the N-terminus of ADM, retains ADM in the circulation, and mobilizes interstitial ADM to increase the level of active bio-ADM, ultimately stabilizing blood vessels. Enibarcimab can be used in research related to septic shock and acute heart failure.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度 : 99.68%
- CAS 番号: 2305638-98-4
- 分子量:145.82 kDa
-
保管条件:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
生物活性
製品説明
IC50 & Target
Adrenomedullin
体外実験
Enibarcimab binds to the N-terminus of ADM with high affinity to form a complex. The Enibarcimab-ADM complex cannot freely cross the endothelial barrier into the interstitial space, leading to the accumulation of bio-ADM in the vascular lumen, thereby stabilizing the vascular barrier and reducing edema and congestion[1][2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
アプリケーション
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized Adrenomedullin/ADM Protein, Human can bind Enibarcimab. The EC50 for this effect is 11.77 ng/mL.
Product Details
-
CAS 番号 2305638-98-4
-
アクセッション番号 P35318
-
分子量 145.82 kDa
-
Species Reactivity
Human
-
Conjugated
Unconjugated
-
Isotype
Human IgG1 kappa
-
Recommend Isotype Controls
-
Format
-
Human IgG1 kappa
-
Product Properties
-
性状
Liquid
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
純度
99.68%
-
Reconstitution
The product can be reconstituted/diluted with sterile PBS or saline.
-
Storage & Stability
Please store the product under the recommended conditions in the Certificate of Analysis.
-
輸送条件
Shipping with dry ice.
Publications (1)
-
Journal Impact Factor
-
Most Recent
純度とドキュメンテーション
-
データシート (257 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
参考文献
[1].
Knothe C, et al; ADRENOSS-2 Investigators. Enibarcimab for the treatment of septic shock in patients selected by a combination of the biomarkers bio-ADM and DPP3: A prespecified subgroup analysis of the AdrenOSS-2 trial. J Crit Care. 2025 Aug;88:155077.
[Content Brief]
[2]. Hartopo AB, et al. The ADESTE trial: A phase 2 study of enibarcimab, a monoclonal antibody targeting adrenomedullin, in acute heart failure. ESC Heart Fail. 2025;12(3):1848-1860. [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)